ROCKET PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.4 USD | -5.21% |
|
-3.26% | -24.21% |
Presenter SpeechEric Joseph (Analysts)Okay. Good afternoon. I'm Eric Joseph, senior biotech an...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
23.63
USD
Average target price
50.31
USD
Spread / Average Target
+112.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.21% | 2.14B | |
| -3.05% | 104B | |
| +0.41% | 97.42B | |
| +0.84% | 22.2B | |
| -18.01% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.23% | 15.06B | |
| +4.29% | 13.98B | |
| +30.76% | 11.66B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Transcript : Rocket Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 02
